Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial

Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial
Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain areas that are particularly affected by Alzheimer’s. The concept is based on findings showing that chronic stress and elevated cortisol levels lead to changes in the brain that affect memory, the development of amyloid plaques, and the death of neurons. The development of Xanamem is also su
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *